v3.26.1
Critical accounting estimates and judgements (Details)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
MTX228 tolimidone acquired IPRD* [member]      
IfrsStatementLineItems [Line Items]      
% change in fair value [1] 40.00% 41.00% 18.00%
MTX230 eRapa acquired IPRD* [member]      
IfrsStatementLineItems [Line Items]      
% change in fair value [1] 20.00% 19.00%  
[1] asset is not yet in use and has not started amortising